Jean‐Louis Payen, Jacques Izopet, Virginie Galindo‐Migeot, Valérie Lauwers‐Cances, Jean‐Pierre Zarski, Jean‐Marie Seigneurin, Elizabeth Dussaix, Jean‐Jacques Voigt, Janick Selves, Karl Barange, Jacqueline Puel, Jean‐Pierre Pascal, Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.vhc) – 30 December 2003 – We studied the efficacy of three interferon alfa‐2b (IFN‐α2b) regimens for the retreatment of patients with chronic hepatitis C (CHC) with prior complete response followed by relapse.

Jacquelyn J. Maher – 30 December 2003

M. Eugenia Guicciardi, Gregory J. Gores – 30 December 2003

C Tibbs, P Donaldson, J Underhill, L Thomson, K Manabe, R Williams – 1 December 1996 – In the search for factors which may influence susceptibility to and outcome from chronic hepatitis C virus (HCV) infection, few studies have considered the influence of host genes. In the present investigation we have performed HLA DRB1, DQA1, DQB1, and DPB1 genotyping on 104 northern European patients with chronic HCV infection and 177 racially and geographically matched controls.

J S McMillan, D S Bowden, P W Angus, G W McCaughan, S A Locarnini – 1 December 1996 – Recurrent hepatitis B virus (HBV) infection is a major problem in patients undergoing liver transplantation. Previously, we reported that infection with HBV strains containing a mutation in the precore region (G‐to‐A at nucleotide 1896) was associated with severe recurrent disease posttransplantation. In this study we investigated other mutations in the precore/core gene and core promoter which may be associated with this severe recurrence.

M Pirlich, O Selberg, K Boker, M Schwarze, M J Muller – 1 December 1996 – The creatinine‐method to estimate muscle mass is frequently used in clinical studies, although the validity of this approach is uncertain in patients with cirrhosis. In this study 102 patients with cirrhosis differing in cause, clinical state, liver, and renal function were investigated to determine whether reduced liver or renal function may explain in part the low levels of urinary creatinine excretion frequently observed in these patients.

P Sauer, L Theilmann, S Herrmann, T Bruckner, T Roeren, G Richter, W Stremmel, A Stiehl – 1 December 1996 – Development of stenosis or occlusion of the transjugular intrahepatic portosystemic stent shunt (TIPSS) is one of the major limiting factors in the long‐term viability of this procedure. The efficacy of anticoagulation with heparin which is used in different centers is still unclear.

N A Terrault, S Zhou, C Combs, J A Hahn, J R Lake, J P Roberts, N L Ascher, T L Wright – 1 December 1996 – Prophylactic hepatitis B immunoglobulin (HBIg) reduces the risk of reinfection in hepatitis B surface antigen (HBsAg)‐positive liver transplant recipients. In the medical center of this study, high‐dose HBIg immunoprophylaxis is administered at a fixed dose of 10,000 IU monthly, and in this study, the long‐term efficacy of this treatment regimen was examined.

A Robert, O Chazouilleres – 1 December 1996 – Prothrombin time (PT) is a universal indicator of liver disease severity. However, variability in thromboplastin reagents leads to large interlaboratory differences in PT results. The aim of this study was to determine whether the use of the international normalized ratio (INR) or other modes of expression might achieve PT standardization in patients with liver failure.

D E Cohen, M Fuchs – 1 December 1996